Evaluation of lansoprazole as a probe for assessing cytochrome P450 2C19 activity and genotype-phenotype correlation in childhood

European Journal of Clinical Pharmacology

Volumn 68, Issue 5, 2012, Pages 629-636

  Gumus, Ersin ^a   Karaca, Ozgur ^a   Babaoglu, Melih O ^a   Baysoy, Gökhan ^a   Balamtekin, Necati ^a   Demir, Hulya ^a   Uslu, Nuray ^a   Bozkurt, Atilla ^a   Yuce, Aysel ^a   Yasar, Umit ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Children; CYP2C19; Genotyping; Lansoprazole; Phenotyping

Indexed keywords

5 HYDROXYLANSOPRAZOLE; 5 HYDROXYOMEPRAZOLE; CYTOCHROME P450 2C19; DRUG METABOLITE; LANSOPRAZOLE; OMEPRAZOLE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; ASIAN; CHILD; CONTROLLED STUDY; CYP2C19 GENE; DRUG BLOOD LEVEL; DYSPEPSIA; ENZYME ACTIVITY; ENZYME ANALYSIS; ESOPHAGITIS; FEMALE; GASTRITIS; GASTROESOPHAGEAL REFLUX; GENE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; HELICOBACTER INFECTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; POPULATION GENETICS; PRIORITY JOURNAL; SINGLE DRUG DOSE; TURKISH; VOMITING;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADOLESCENT; ARYL HYDROCARBON HYDROXYLASES; BIOTRANSFORMATION; CHILD; CHILD, PRESCHOOL; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; H(+)-K(+)-EXCHANGING ATPASE; HOSPITALS, PEDIATRIC; HUMANS; MALE; OMEPRAZOLE; PHARMACOGENETICS; POLYMORPHISM, GENETIC; PROTON PUMP INHIBITORS; TURKEY;

EID: 84864287845     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-011-1151-z     Document Type: Article

References (41)

1. Goldstein JA (2001) Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol 52:349-355 (Pubitemid 32939439)
2. Rosemary J, Adithan C (2007) The pharmacogenetics of CYP2C9 and CYP2C19: ethnic variation and clinical significance. Curr Clin Pharmacol 2:93-109 (Pubitemid 46729082)
3. Zhou SF, Liu JP, Chowbay B (2009) Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev 41:89-295
4. de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA (1994) The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 269:15419-15422
5. Brosen K, de Morais SM, Meyer UA, Goldstein JA (1995) A multifamily study on the relationship between CYP2C19 genotype and s-mephenytoin oxidation phenotype. Pharmacogn 5:312-317
6. Sim SC, Risinger C, Dahl ML, Aklillu E, Christensen M, Bertilsson L, Ingelman-Sundberg M (2006) A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 79:103-113 (Pubitemid 43069582)
7. *17 allele on serum concentration of escitalopram in psychiatric patients. Clin Pharmacol Ther 83:322-327
8. *17 allele; a pharmacokinetic study in healthy volunteers. Brit J Clin Pharm 65:767-774 (Pubitemid 351535091)
9. *17 is associated with decreased breast cancer risk. Breast Cancer Res Treat 115:391-396
10. *17 discovery: the case of Greece. Pharmacogn 10:43-49
11. Gawronska-Szklarz B, Siuda A, Kurzawski M, Bielicki D, Marlicz W, Drozdzik M (2010) Effects of CYP2C19, MDR1, and interleukin 1-B gene variants on the eradication rate of Helicobacter pylori infection by triple therapy with pantoprazole, amoxicillin, and metronidazole. Eur J Clin Pharmacol 66:681-687
12. Sim SC, Nordin L, Andersson TM, Virding S, Olsson M, Pedersen NL, Ingelman-Sundberg M (2010) Association between CYP2C19 polymorphism and depressive symptoms. Am J Med Genet B Neuropsychiatr Genet 153B:1160-1166
13. Miura J, Obua C, Abbo C, Kaneko S, Tateishi T (2009) Cytochrome P450 2C19 genetic polymorphisms in Ugandans. Eur J Clin Pharmacol 65:319-320
14. Chen L, Qin S, Xie J, Tang J, Yang L, Shen W, Zhao X, Du J, He G, Feng G, He L, Xing Q (2008) Genetic polymorphism analysis of CYP2C19 in Chinese Han populations from different geographic areas of mainland China. Pharmacogn 9:691-702
15. *17 allele and its minor role in a Japanese population. Br J Clin Pharmacol 65:437-439 (Pubitemid 351316919)
16. Kim KA, Song WK, Park JY (2009) Association of CYP2B6, CYP3A5, and CYP2C19 genetic polymorphisms with sibutramine pharmacokinetics in healthy Korean subjects. Clin Pharmacol Ther 86:511-518
17. Desta Z, Modak A, Nguyen PD, Lemler SM, Kurogi Y, Li L, Flockhart DA (2009) Rapid identification of the hepatic cytochrome P450 2C19 activity using a novel and noninvasive [13C] pantoprazole breath test. J Pharmacol Exp Ther 329:297-305
18. Collet JP, Hulot JS, Pena A, Villard E, Esteve JB, Silvain J, Payot L, Brugier D, Cayla G, Beygui F, Bensimon G, Funck-Brentano C, Montalescot G (2009) Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 373:309-317
19. Streetman DS, Bertino JS Jr, Nafziger AN (2000) Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogn 10:187-216 (Pubitemid 30242736)
20. Furuta T, Kodaira C, Nishino M, Yamade M, Sugimoto M, Ikuma M, Hishida A, Watanabe H, Umemura K (2009) [13C]-pantoprazole breath test to predict CYP2C19 phenotype and efficacy of a proton pump inhibitor, lansoprazole. Aliment Pharmacol Ther 30:294-300
21. de Wildt SN, Ito S, Koren G (2009) Challenges for drug studies in children: CYP3A phenotyping as example. Drug Discov Today 14:6-15
22. Rane A (1999) Phenotyping of drug metabolism in infants and children: potentials and problems. Pediatrics 104:640-643 (Pubitemid 29426637)
23. Tran A, Rey E, Pons G, Pariente-Khayat A, D'Athis P, Sallerin V, Dupont C (2002) Pharmacokinetic-pharmacodynamic study of oral lansoprazole in children. Clin Pharmacol Ther 71:359-367 (Pubitemid 34518146)
24. Pearce RE, Rodrigues AD, Goldstein JA, Parkinson A (1996) Identification of the human P450 enzymes involved in lansoprazole metabolism. J Pharmacol Exp Ther 277:805-816 (Pubitemid 27168992)
25. Shi S, Klotz U (2008) Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol 64:935-951
26. Andersson T (1996) Pharmacokinetics, metabolism and interactions of acid pump inhibitors. focus on omeprazole, lansoprazole and pantoprazole. Clin Pharmacokinet 31:9-28 (Pubitemid 26238200)
27. Herrlin K, Massele AY, Jande M, Alm C, Tybring G, Abdi YA, Wennerholm A, Johansson I, Dahl ML, Bertilsson L, Gustafsson LL (1998) Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype. Clin Pharmacol Ther 64:391-401 (Pubitemid 28473765)
28. Laine K, Tybring G, Bertilsson L (2000) No sex-related differences but significant inhibition by oral contraceptives of CYP2C19 activity as measured by the probe drugs mephenytoin and omeprazole in healthy Swedish white subjects. Clin Pharmacol Ther 68:151-159 (Pubitemid 30659170)
29. Goldstein JA, Blaisdell J (1996) Genetic tests which identify the principal defects in CYP2C19 responsible for the polymorphism in mephenytoin metabolism. Methods: Enzymol 272:210-218 (Pubitemid 26299884)
30. Uno T, Yasui-Furukori N, Takahata T, Sugawara K, Tateishi T (2005) Determination of lansoprazole and two of its metabolites by liquid-liquid extraction and automated column-switching highperformance liquid chromatography: application to measuring CYP2C19 activity. J Chromatogr B Analyt Technol Biomed Life Sci 816:309-314 (Pubitemid 40143518)
31. Tamminga WJ, Wemer J, Oosterhuis B, Wieling J, Touw DJ, de Zeeuw RA, de Leij LF, Jonkman JH (2001) Mephenytoin as a probe for CYP2C19 phenotyping: effect of sample storage, intraindividual reproducibility and occurrence of adverse events. Br J Clin Pharmacol 51:471-474 (Pubitemid 32852985)
32. Yin OQ, Tomlinson B, Chow AH, Waye MM, Chow MS (2004) Omeprazole as a CYP2C19 marker in Chinese subjects: assessment of its gene-dose effect and intrasubject variability. J Clin Pharmacol 44:582-589 (Pubitemid 38668020)
33. Basci NE, Bozkurt A, Kortunay S, Isimer A, Sayal A, Kayaalp SO (1996) Proguanil metabolism in relation to S-mephenytoin oxidation in a Turkish population. Br J Clin Pharmacol 42:771-773 (Pubitemid 26417620)
34. Kortunay S, Basci NE, Bozkurt A, Isimer A, Sayal A, Kayaalp SO (1997) The hydroxylation of omeprazole correlates with S-mephenytoin and proguanil metabolism. Eur J Clin Pharmacol 53:261-264 (Pubitemid 28018302)
35. Furuta T, Kodaira C, Nishino M, Yamade M, Sugimoto M, Ikuma M, Hishida A, Watanabe H, Umemura K (2009) 13c-Pantoprazole Breath Test to Predict Cyp2c19 Phenotypes and Efficacy of Proton Pump Inhibitor. Clin Pharmacol Ther 85:S67-S67
36. *17 and metabolism of amitriptyline, citalopram and clomipramine in Dutch hospitalized patients. Pharmacogenomics J
37. *17 allele in healthy subjects. Eur J Clin Pharmacol 64:1175-1179
38. *17 allele on the pharmacokinetics of omeprazole and pantoprazole in children: evidence for a differential effect. Drug Metab Dispos 38:894-897
39. Ramsjo M, Aklillu E, Bohman L, Ingelman-Sundberg M, Roh HK, Bertilsson L (2010) CYP2C19 activity comparison between Swedes and Koreans: effect of genotype, sex, oral contraceptive use, and smoking. Eur J Clin Pharmacol 66:871-877
40. Kim MJ, Nafziger AN, Zhang Y, Sellers EM, Gaedigk A, Bertino JS Jr (2004) Lack of weight-based dose dependency and intraindividual variability of omeprazole for CYP2C19 phenotyping. J Clin Pharmacol 44:966-973 (Pubitemid 39096811)
41. Strom CM, Goos D, Crossley B, Zhang K, Buller-Burkle A, Jarvis M, Quan F, Peng M, Sun W (2011) Testing for variants in CYP2C19: population frequencies and testing experience in a clinical laboratory. Genet Med